Yang Pao-Pao, Yeh Geng-Chang, Yeh Teng-Kuang, Xi Jinghua, Loh Horace H, Law Ping-Yee, Tao Pao-Luh
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC; Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan, ROC.
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC.
Pharmacol Res. 2016 Sep;111:867-876. doi: 10.1016/j.phrs.2016.05.034. Epub 2016 Aug 2.
Oxycodone has been used clinically for over 90 years. While it is known that it exhibits low affinity for the multiple opioid receptors, whether its pharmacological activities are due to oxycodone activation of the opioid receptor type or due to its active metabolite (oxymorphone) that exhibits high affinity for the mu-opioid receptors remains unresolved. Ross and Smith (1997) reported the antinociceptive effects of oxycodone (171nmol, i.c.v.) are induced by putative kappa-opioid receptors in SD rat while others have reported oxycodone activities are due to activation of mu- and/or delta-opioid receptors. In this study, using male mu-opioid receptor knock-out (MOR-KO) mice, we examined whether delta-opioid receptor was involved in oxycodone antinociception. Systemic subcutaneous (s.c.) administration of oxycodone (above 40mg/kg) could induce a small but significant antinociceptive effect in MOR-KO mice by the tail flick test. Delta-opioid receptor antagonist (naltrindole, 10mg/kg or 20mg/kg, i.p.) could block this effect. When oxycodone was injected directly into the brain of MOR-KO mice by intracerebroventricular (i.c.v.) route, oxycodone at doses of 50nmol or higher could induce similar level of antinociceptive responses to those observed in wild type mice at the same doses by i.c.v. Delta-opioid receptor antagonists (naltrindole at 10nmol or ICI 154,129 at 20μg) completely blocked the supraspinal antinociceptive effect of oxycodone in MOR-KO mice. Such oxycodone antinociceptive responses were probably not due to its active metabolites oxymorphone because (a) the relative low level of oxymorphone was found in the brain after systemically or centrally oxycodone injection using LC/MS/MS analysis; (b) oxymorphone at a dose that mimics the level detected in the mice brain did not show any significant antinocieption effect; (c) oxycodone exhibits equal potency as oxymorphone albeit being a partial agonist in regulating [Ca(2+)]I transients in a clonal cell line expressing high level of mu-opioid receptor. These data suggest that oxycodone by itself can activate both the mu- and delta-opioid receptors and that delta-opioid receptors may contribute to the central antinociceptive effect of oxycodone in mice.
羟考酮已在临床上使用了90多年。虽然已知它对多种阿片受体的亲和力较低,但其药理活性是由于羟考酮对阿片受体类型的激活,还是由于其对μ-阿片受体具有高亲和力的活性代谢物(羟吗啡酮),仍未得到解决。罗斯和史密斯(1997年)报告称,羟考酮(171纳摩尔,脑室内注射)的抗伤害感受作用是由SD大鼠中假定的κ-阿片受体诱导的,而其他人则报告称羟考酮的活性是由于μ-和/或δ-阿片受体的激活。在本研究中,我们使用雄性μ-阿片受体基因敲除(MOR-KO)小鼠,研究δ-阿片受体是否参与羟考酮的抗伤害感受作用。通过甩尾试验,对MOR-KO小鼠全身皮下注射(s.c.)羟考酮(40mg/kg以上)可诱导出小但显著的抗伤害感受作用。δ-阿片受体拮抗剂(纳曲吲哚,10mg/kg或20mg/kg,腹腔注射)可阻断此作用。当通过脑室内(i.c.v.)途径将羟考酮直接注射到MOR-KO小鼠脑中时,50纳摩尔或更高剂量的羟考酮可诱导出与野生型小鼠经相同剂量脑室内注射时观察到的类似水平的抗伤害感受反应。δ-阿片受体拮抗剂(10纳摩尔的纳曲吲哚或20微克的ICI 154,129)完全阻断了羟考酮对MOR-KO小鼠的脊髓上抗伤害感受作用。这种羟考酮的抗伤害感受反应可能不是由于其活性代谢物羟吗啡酮,因为:(a)使用LC/MS/MS分析,在全身或中枢注射羟考酮后,在脑中发现的羟吗啡酮水平相对较低;(b)模拟在小鼠脑中检测到的水平的羟吗啡酮剂量未显示出任何显著的抗伤害感受作用;(c)尽管羟考酮在调节表达高水平μ-阿片受体的克隆细胞系中的[Ca(2+)]I瞬变方面是部分激动剂,但其效力与羟吗啡酮相当。这些数据表明,羟考酮本身可以激活μ-和δ-阿片受体,并且δ-阿片受体可能有助于羟考酮对小鼠的中枢抗伤害感受作用。